P8IP
MRTX

Pier 88 Investment Partners’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Pier 88 Investment Partners’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,440
Closed -$716K – 102
2023
Q3 		$716K Buy
16,440
+8,550
+108% +$305K 0.18% 70
2023
Q2 		$285K Buy
7,890
+450
+6% +$18.5K 0.07% 83
2023
Q1 		$277K Buy
7,440
+3,350
+82% +$151K 0.07% 76
2022
Q4 		$185K Sell
4,090
-5,310
-56% -$344K 0.04% 79
2022
Q3 		$656K Sell
9,400
-1,960
-17% -$145K 0.16% 73
2022
Q2 		$763K Buy
11,360
+7,160
+170% +$455K 0.18% 74
2022
Q1 		$345K Hold
4,200
– – 0.12% 71
2021
Q4 		$616K Buy
4,200
+500
+14% +$77.6K 0.13% 83
2021
Q3 		$654K Buy
3,700
+3,330
+900% +$536K 0.2% 82
2021
Q2 		$60K Sell
370
-2,970
-89% -$477K 0.02% 106
2021
Q1 		$572K Hold
3,340
– – 0.19% 86
2020
Q4 		$734K Buy
3,340
+110
+3% +$23.8K 0.24% 86
2020
Q3 		$536K Buy
+3,230
New +$442K 0.16% 92
2020
Q2 		– Sell
-5,750
Closed -$442K – 118
2020
Q1 		$442K Buy
5,750
+3,600
+167% +$323K 0.16% 80
2019
Q4 		$277K Buy
+2,150
New +$207K 0.11% 77

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

Pier 88 Investment Partners's MRTX Position: Q4 2023 in Review

Pier 88 Investment Partners sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 16,440 shares — an estimated $716K sold.

Pier 88 Investment Partners first reported a position in MRTX in Q4 2019 and held it in 15 quarters. The position peaked at $763K in Q2 2022. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • Pier 88 Investment Partners reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Pier 88 Investment Partners sold 16,440 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $716K.
  • Pier 88 Investment Partners first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2019 and held it in 15 quarters.
  • Pier 88 Investment Partners's Mirati Therapeutics, Inc. Common Stock position peaked at $763K in Q2 2022.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Pier 88 Investment Partners's 13F filing for Q4 2023, filed 12 Feb 2024.